Adocia Today Announces the Release of Its Interim Financial Report as of June 30, 2016

Regulatory News:

ADOCIA (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) today announces the release of its interim financial report.

Following the July 20, 2016 press release announcing the financial results of the first half of 2016, Adocia today announces the release of its interim financial report as of June 30, 2016.

The report includes the responsibility statement, the interim management report, the interim consolidated financial statements and the statutory auditors’ review report.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone^® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia aims to deliver "Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160721006090/en/